JP2025004002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025004002A5 JP2025004002A5 JP2024159834A JP2024159834A JP2025004002A5 JP 2025004002 A5 JP2025004002 A5 JP 2025004002A5 JP 2024159834 A JP2024159834 A JP 2024159834A JP 2024159834 A JP2024159834 A JP 2024159834A JP 2025004002 A5 JP2025004002 A5 JP 2025004002A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- variant
- terminus
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 claims 20
- 101150055528 SPAM1 gene Proteins 0.000 claims 20
- 125000000539 amino acid group Chemical group 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 238000012217 deletion Methods 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 238000003259 recombinant expression Methods 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- -1 T475 Substances 0.000 claims 2
- 239000003996 polyglycerol polyricinoleate Substances 0.000 claims 2
- 239000001957 sucroglyceride Substances 0.000 claims 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0086308 | 2018-07-25 | ||
| KR20180086308 | 2018-07-25 | ||
| KR10-2019-0029758 | 2019-03-15 | ||
| KR20190029758 | 2019-03-15 | ||
| PCT/KR2019/009215 WO2020022791A1 (ko) | 2018-07-25 | 2019-07-25 | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
| JP2020500863A JP7204729B2 (ja) | 2018-07-25 | 2019-07-25 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP2022211105A JP2023052142A (ja) | 2018-07-25 | 2022-12-28 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211105A Division JP2023052142A (ja) | 2018-07-25 | 2022-12-28 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025004002A JP2025004002A (ja) | 2025-01-14 |
| JP2025004002A5 true JP2025004002A5 (https=) | 2025-03-19 |
Family
ID=69182377
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500863A Active JP7204729B2 (ja) | 2018-07-25 | 2019-07-25 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP2022211105A Pending JP2023052142A (ja) | 2018-07-25 | 2022-12-28 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP2024159834A Pending JP2025004002A (ja) | 2018-07-25 | 2024-09-17 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500863A Active JP7204729B2 (ja) | 2018-07-25 | 2019-07-25 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP2022211105A Pending JP2023052142A (ja) | 2018-07-25 | 2022-12-28 | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12371683B2 (https=) |
| EP (1) | EP3636752A4 (https=) |
| JP (3) | JP7204729B2 (https=) |
| KR (3) | KR20210023798A (https=) |
| CN (5) | CN118773171B (https=) |
| AU (3) | AU2019311658B2 (https=) |
| BR (1) | BR112020019041A2 (https=) |
| CA (1) | CA3093885A1 (https=) |
| MX (1) | MX2020009824A (https=) |
| WO (1) | WO2020022791A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| KR102650991B1 (ko) * | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| CN120699939A (zh) | 2020-01-23 | 2025-09-26 | 阿特根公司 | 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物 |
| IL299205A (en) | 2020-07-17 | 2023-02-01 | Geron Corp | Subcutaneous telomerase inhibitor preparations and methods of using them |
| US12221638B2 (en) * | 2020-08-07 | 2025-02-11 | Alteogen Inc. | Method for producing recombinant hyaluronidase |
| JP2023545926A (ja) | 2020-09-24 | 2023-11-01 | メルク・シャープ・アンド・ドーム・エルエルシー | プログラム死受容体１（ｐｄ－１）抗体とヒアルロニダーゼ変異体とそれらのフラグメントとの安定製剤およびその使用方法 |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| TW202305009A (zh) | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| CN115671267A (zh) | 2021-07-23 | 2023-02-03 | 上海宝济药业有限公司 | 一种皮下抗生素药物组合物 |
| KR20240040104A (ko) | 2021-08-02 | 2024-03-27 | 아르젠엑스 비브이 | 피하 단위 투여 형태 |
| KR20240055077A (ko) | 2021-09-14 | 2024-04-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 히알루로니데이스를 이용한 농축된 항체 제형의 촉진된 전달 |
| JP2024541973A (ja) * | 2021-10-29 | 2024-11-13 | アルテオジェン・インコーポレイテッド | ヒトヒアルロニダーゼｐｈ２０及び薬物を含む医薬組成物 |
| EP4469586A1 (en) | 2022-03-01 | 2024-12-04 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| CN114573715A (zh) * | 2022-03-14 | 2022-06-03 | 江苏雅酶医药科技有限公司 | 一种重组长效人透明质酸酶及其生产方法和应用 |
| JP2025513510A (ja) | 2022-04-20 | 2025-04-24 | アルトス バイオロジックス インク． | オクレリズマブを含む薬学的組成物とその用途 |
| KR20250022071A (ko) | 2022-06-02 | 2025-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항체 조성물 및 이의 이용 방법 |
| KR102774438B1 (ko) * | 2022-06-08 | 2025-02-27 | (주)한국비엠아이 | 히알루로니다제 폴리펩티드 및 이의 용도 |
| CA3240340A1 (en) * | 2022-06-22 | 2023-12-28 | Soon Jae Park | N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof |
| KR102621518B1 (ko) * | 2022-06-29 | 2024-01-10 | 주식회사 오디스젠 | 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체 |
| CN119421949A (zh) * | 2022-06-29 | 2025-02-11 | 奥德斯根株式会社 | 中性pH中显示活性的透明质酸酶Hyal1变体 |
| CA3263055A1 (en) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) AND RHUPH20 ANTIBODIES OR VARIANTS OR FRAGMENTS THEREOF |
| US20260035465A1 (en) * | 2022-07-28 | 2026-02-05 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof |
| KR20240038901A (ko) * | 2022-09-16 | 2024-03-26 | (주)피앤피바이오팜 | 신규한 히알루로니다제 ph-20 변이체 및 그 용도 |
| EP4637716A1 (en) | 2022-12-22 | 2025-10-29 | Halozyme, Inc. | Hyaluronidase enzyme formulations for high volume administration |
| JP2026511560A (ja) * | 2023-03-23 | 2026-04-14 | アルテオジェン・インコーポレイテッド | 新規ヒアルロン酸加水分解酵素変異体及びこれを含む薬剤学的組成物 |
| KR20250086876A (ko) * | 2023-12-06 | 2025-06-16 | (주)한국비엠아이 | 히알루로니다제 폴리펩티드와 약물을 포함하는 피하투여용 조성물 |
| WO2025136032A1 (ko) * | 2023-12-21 | 2025-06-26 | 주식회사 오디스젠 | 개선된 특성을 갖는 히알루로니다제 hyal2 변이체 |
| KR102896967B1 (ko) * | 2023-12-21 | 2025-12-09 | 주식회사 오디스젠 | 개선된 특성을 갖는 히알루로니다제 Hyal2 변이체 |
| KR102875495B1 (ko) * | 2023-12-28 | 2025-10-27 | 주식회사 오디스젠 | 히알루로니다제 Hyal1 변이체 |
| WO2025168089A1 (zh) | 2024-02-08 | 2025-08-14 | 上海宝济药业股份有限公司 | 用于皮下给药的药物组合及其应用 |
| WO2025264960A1 (en) | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-13 and antibodies that bind ox40l |
| WO2025264972A1 (en) | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-4r alpha and antibodies that bind |
| WO2026001707A1 (zh) * | 2024-06-27 | 2026-01-02 | 上海复宏汉霖生物技术股份有限公司 | 一种新型透明质酸酶变体 |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
| WO2026085415A1 (en) | 2024-10-18 | 2026-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof |
| WO2026085419A2 (en) | 2024-10-18 | 2026-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof |
| WO2026085414A1 (en) | 2024-10-18 | 2026-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof |
| WO2026085417A2 (en) | 2024-10-18 | 2026-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof |
| CN119776311B (zh) * | 2024-12-13 | 2025-12-19 | 江南大学 | 一种透明质酸合酶突变体及其应用 |
| CN121737095A (zh) * | 2026-02-28 | 2026-03-27 | 齐鲁制药有限公司 | 透明质酸酶ph20多肽修饰变体、组合物及应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
| US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
| US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| EP1945662A2 (en) | 2005-11-10 | 2008-07-23 | Receptor Biologix, Inc. | Methods for production of receptor and ligand isoforms |
| RU2471867C2 (ru) | 2007-06-19 | 2013-01-10 | Тамара П. Уваркина | Гиалуронидаза и способ ее применения |
| ITMI20072225A1 (it) | 2007-11-23 | 2009-05-24 | Luso Farmaco Inst | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
| SI4269578T1 (sl) | 2008-03-06 | 2024-07-31 | Halozyme, Inc. | Sestava topne hialuronidaze |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| KR20130116386A (ko) * | 2008-04-14 | 2013-10-23 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| EA022752B1 (ru) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
| ES2573462T3 (es) | 2008-12-09 | 2016-06-08 | Halozyme, Inc. | Polipéptidos de PH20 soluble extendida y usos de los mismos |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| WO2010138918A1 (en) | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| HUE028832T2 (en) | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| NZ618331A (en) | 2011-06-17 | 2016-04-29 | Halozyme Inc | Stable formulations of a hyaluronan-degrading enzyme |
| WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| CN103173474B (zh) | 2013-03-27 | 2014-08-27 | 广州白云山拜迪生物医药有限公司 | 一种用于cho细胞表达可溶性重组人透明质酸酶ph20的基因序列 |
| US9515094B2 (en) | 2013-06-26 | 2016-12-06 | Semiconductor Energy Laboratory Co., Ltd. | Storage device and semiconductor device |
| TW201534726A (zh) * | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| CA2930277A1 (en) | 2013-11-13 | 2015-05-21 | Tillotts Pharma Ag | Multi-particulate drug delivery system |
| JP2017507900A (ja) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| WO2016017736A1 (ja) | 2014-07-31 | 2016-02-04 | 国立大学法人神戸大学 | 分泌シグナルペプチドならびにそれを利用したタンパク質の分泌および細胞表層提示 |
| PT3186281T (pt) * | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| CN104745553B (zh) | 2015-03-27 | 2017-11-28 | 杭州北斗生物技术有限公司 | 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法 |
| CA2896038C (en) | 2015-07-03 | 2022-08-09 | Glycobiosciences Inc. | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof |
| US9995753B2 (en) | 2015-09-25 | 2018-06-12 | Merck Sharp & Dohme Corp. | Anti-pembrolizumab antibodies |
| CA3004152C (en) | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| CN105567606B (zh) | 2016-03-02 | 2019-03-19 | 青岛海洋生物医药研究院股份有限公司 | 一种球形节杆菌及其产生的透明质酸酶 |
| US11660354B2 (en) | 2016-11-30 | 2023-05-30 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| PT3589661T (pt) | 2017-03-02 | 2024-01-29 | Genentech Inc | Tratamento com adjuvante de cancro da mama positivo para her2 |
| EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| CA3131019A1 (en) | 2019-02-22 | 2020-08-27 | Memorial Sloan Kettering Cancer Center | Cd33 antibodies and methods of using the same to treat cancer |
| KR102650991B1 (ko) | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| JP2020197994A (ja) | 2019-06-04 | 2020-12-10 | 東芝テック株式会社 | 情報処理装置及びその制御プログラム |
| CN120699939A (zh) | 2020-01-23 | 2025-09-26 | 阿特根公司 | 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物 |
| US12221638B2 (en) | 2020-08-07 | 2025-02-11 | Alteogen Inc. | Method for producing recombinant hyaluronidase |
| JP2023545926A (ja) | 2020-09-24 | 2023-11-01 | メルク・シャープ・アンド・ドーム・エルエルシー | プログラム死受容体１（ｐｄ－１）抗体とヒアルロニダーゼ変異体とそれらのフラグメントとの安定製剤およびその使用方法 |
| JP2024541973A (ja) | 2021-10-29 | 2024-11-13 | アルテオジェン・インコーポレイテッド | ヒトヒアルロニダーゼｐｈ２０及び薬物を含む医薬組成物 |
-
2019
- 2019-07-25 MX MX2020009824A patent/MX2020009824A/es unknown
- 2019-07-25 CN CN202411131388.9A patent/CN118773171B/zh active Active
- 2019-07-25 CN CN201980023392.4A patent/CN111971387A/zh active Pending
- 2019-07-25 KR KR1020207024813A patent/KR20210023798A/ko active Pending
- 2019-07-25 CN CN202411133487.0A patent/CN118755703A/zh active Pending
- 2019-07-25 BR BR112020019041-1A patent/BR112020019041A2/pt unknown
- 2019-07-25 US US16/628,258 patent/US12371683B2/en active Active
- 2019-07-25 CN CN202411131157.8A patent/CN118853631A/zh active Pending
- 2019-07-25 CN CN202411127100.0A patent/CN118792283A/zh active Pending
- 2019-07-25 WO PCT/KR2019/009215 patent/WO2020022791A1/ko not_active Ceased
- 2019-07-25 JP JP2020500863A patent/JP7204729B2/ja active Active
- 2019-07-25 KR KR1020207002955A patent/KR102151388B1/ko active Active
- 2019-07-25 AU AU2019311658A patent/AU2019311658B2/en active Active
- 2019-07-25 EP EP19827585.1A patent/EP3636752A4/en active Pending
- 2019-07-25 KR KR1020257002900A patent/KR20250021616A/ko active Pending
- 2019-07-25 CA CA3093885A patent/CA3093885A1/en active Pending
-
2022
- 2022-12-28 JP JP2022211105A patent/JP2023052142A/ja active Pending
-
2023
- 2023-01-20 AU AU2023200324A patent/AU2023200324B9/en active Active
-
2024
- 2024-09-17 JP JP2024159834A patent/JP2025004002A/ja active Pending
-
2025
- 2025-06-06 US US19/231,008 patent/US20250368976A1/en active Pending
- 2025-12-03 AU AU2025275191A patent/AU2025275191A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025004002A5 (https=) | ||
| JP2025066711A5 (https=) | ||
| JP2024028452A5 (https=) | ||
| JP2022062113A5 (https=) | ||
| JP2022500017A5 (https=) | ||
| DK166784B1 (da) | Rekombinant dna-sekvens, en mikroorganisme indeholdende sekvensen og en fremgangsmaade til fremstilling af et eucaryot protein | |
| JPH09322781A5 (https=) | ||
| JP2007513634A5 (https=) | ||
| KR20000019788A (ko) | 대장균 엔테로톡신ⅱ 신호펩티드의 변형체와 인체성장호르몬의융합단백질을 발현하는 재조합 미생물 및 그를 이용한 인체성장호르몬의 제조방법 | |
| JP2001513982A5 (https=) | ||
| JP2005253469A5 (https=) | ||
| JP2004532014A5 (https=) | ||
| JP2004041218A5 (https=) | ||
| JP2005509420A5 (https=) | ||
| JPH07215998A (ja) | ヒト−レラキシン遺伝子 | |
| JP2020517260A5 (https=) | ||
| JP2022070902A5 (https=) | ||
| JPWO2023027041A5 (https=) | ||
| CA2636075A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| JP2008545393A5 (https=) | ||
| CN116836955B (zh) | 末端脱氧核苷酸转移酶及其制备方法 | |
| JP2002517193A5 (https=) | ||
| CA2323756A1 (en) | Genetic engineering salt tolerance in crop plants | |
| JPWO2020027010A5 (https=) | ||
| IE52781B1 (en) | Human proinsulin and preproinsulin genes |